Palvella Therapeutics, Inc. (PVLA) Research & Development (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Research & Development for 11 consecutive years, with $2.5 million as the latest value for Q4 2024.
- On a quarterly basis, Research & Development rose 108.91% to $2.5 million in Q4 2024 year-over-year; TTM through Dec 2024 was $8.6 million, a 2.1% decrease, with the full-year FY2024 number at $8.2 million, down 7.3% from a year prior.
- Research & Development was $2.5 million for Q4 2024 at Palvella Therapeutics, down from $3.6 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $18.9 million in Q3 2021 to a low of -$28.6 million in Q4 2023.
- A 5-year average of $9.2 million and a median of $12.4 million in 2020 define the central range for Research & Development.
- Peak YoY movement for Research & Development: tumbled 313.41% in 2023, then skyrocketed 108.91% in 2024.
- Palvella Therapeutics' Research & Development stood at $10.6 million in 2020, then surged by 44.63% to $15.4 million in 2021, then decreased by 12.87% to $13.4 million in 2022, then crashed by 313.41% to -$28.6 million in 2023, then skyrocketed by 108.91% to $2.5 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Research & Development are $2.5 million (Q4 2024), $3.6 million (Q3 2024), and $1.4 million (Q2 2024).